14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
DRIO vs CLPT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, DarioHealth Corp. (DRIO) captures the overall head-to-head institutional edge over ClearPoint Neuro, Inc. (CLPT) on higher Unified Composite conviction (42.2/100 HOLD vs. 40.4/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while CLPT wins 3–2 across the 6-pillar growth and valuation breakdown. DRIO trades at $1.32 (10.6x Forward P/E, -142.7% operating margin) versus CLPT at $6.91 (12.1x Forward P/E, -66.6% operating margin).
Growth vs. Quality Trade-Off: DRIO earns the overall head-to-head edge with a stronger Unified Composite Score (42.2/100 HOLD vs. CLPT 40.4/100 SELL) and 0.45β · 182% Vol risk profile, whereas CLPT leads top-line expansion (+36.3% YoY revenue growth, 0.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: DRIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0); meanwhile CLPT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRIO vs CLPT. Trailing 12-month operating profitability (DRIO -142.7% vs CLPT -66.6%) and valuation multiples (DRIO 10.6x vs CLPT 12.1x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $234.3M market capitalization and -66.6% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DRIO vs CLPT Key Questions & Quantitative Answers
As of Nov 20, 2026, DarioHealth Corp. (DRIO) captures the overall head-to-head institutional edge over ClearPoint Neuro, Inc. (CLPT) on higher Unified Composite conviction (42.2/100 HOLD vs. 40.4/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while CLPT wins 3–2 across the 6-pillar growth and valuation breakdown. DRIO trades at $1.32 (10.6x Forward P/E, -142.7% operating margin) versus CLPT at $6.91 (12.1x Forward P/E, -66.6% operating margin). Growth vs. Quality Trade-Off: DRIO earns the overall head-to-head edge with a stronger Unified Composite Score (42.2/100 HOLD vs. CLPT 40.4/100 SELL) and 0.45β · 182% Vol risk profile, whereas CLPT leads top-line expansion (+36.3% YoY revenue growth, 0.60x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DRIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.0); meanwhile CLPT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CLPT leads the Growth & Scale pillar: DRIO posts +6.1% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.3% gross margin, -142.7% operating margin), compared with CLPT at +36.3% YoY revenue growth and +0.0% YoY earnings growth on $45M TTM revenue (61.4% gross margin, -66.6% operating margin). On trailing 12-month operating scale, DRIO generates $21M in USD-normalized revenue versus $45M for CLPT. In operating R&D and SG&A reinvestment, DRIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLPT.
DRIO screens cheaper on headline valuation multiples. DRIO trades at 10.6x Forward P/E, 10.6x Trailing P/E, N/M PEG, and 0.8x EV/Revenue (-132.8% EBITDA margin), whereas CLPT trades at 12.1x Forward P/E, 12.1x Trailing P/E, 0.60x PEG, and 5.8x EV/Revenue (-73.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DRIO (-46.6% ROE) versus CLPT (-167.5% ROE) capital efficiency.
In options market volatility and institutional positioning, DRIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 182% Vol realized risk). By comparison, CLPT carries 107.7% implied volatility (7th %ile, Compressed (<25th %ile)), a 2.95x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.91β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.